Floatz Rating
CC45/100
Confidence
Indicative
Sponsor
Myeloid Therapeutics
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05138458CT.gov A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL | — | Suspended | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mycosis Fungoides
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| mt-101 (this asset) | Myeloid Therapeutics | P1/2 | CC · 45 |
| Cyclophosphamide | National Cancer Institute (NCI) | P4 | BBB |
| (+)-Vincristine | Virogen Biotechnology Inc. | P4 | BBB |
| Fludarabine | National Cancer Institute (NCI) | P2 | BBB |
| Nivestim | Mayo Clinic | P4 | BBB |
| Adriamycin | Pierluigi Porcu | P4 | BBB |
| Etoposide | Fred Hutchinson Cancer Center | P2 | BBB |
| Dexasone | City of Hope Medical Center | P2 | BBB |
| Cediranib | National Cancer Institute (NCI) | P2 | BB |
+42 more in the Mycosis Fungoides cohort
Other indications for mt-101
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Peripheral T-Cell Lymphoma, Not Otherwise Specified | — | P1/2 | CCC · 48 |
| Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | — | P1/2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. mt-101 in Mycosis Fungoides. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/mt-101-mycosis-fungoides
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →